Try our mobile app

VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention

Published: 2020-07-27 11:00:00 ET
<<<  go to AMRN company page

VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study

First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses, with results consistent across different types of coronary revascularization procedures, including elective, urgent, and emergent interventions

In newly presented data, early coronary revascularization benefit signal shown in a prespecified exploratory analysis, with sustained statistical significance attained by 11 months

DUBLIN, Ireland and BRIDGEWATER, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data from the REDUCE-IT® REVASC analysis, presented as an encore by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD Prevention, showed that administration of 4 g/day of VASCEPA® (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p